Attovia Therapeutics raises $289 million in IPO, adding third I&I drug to market debut
read at Endpoints ↗DealPositive
Attovia Therapeutics, a biotech focused on immunology and inflammation, completed an initial public offering that raised about $289 million.
The funds will support the development of three I&I drug candidates the company is bringing to market, according to CEO Tao Fu.
This IPO marks the third straight week of new biotech listings, a milestone not seen since the winter of 2025, highlighting renewed investor interest in the sector.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Attovia extends biotech IPO streak with $289M listing for three I&I drugs”
read at Endpoints ↗88 words · retrieved Aug 5
comments(0)
5-min edit window · permanent after that